CBIO News and Press, Catalyst Biosciences Inc. From 05/24/22

Snap (SNAP) -30% as it warns on EBITDA, revenues, deteriorating economy; social media peers tumble. BigBear.ai Holdings (BBAI) -26%. Abercrombie & Fitch (ANF) -25% on Q1 earnings release. GeoVax Labs (GOVX) -22% after Moderna enters monkeypox vaccine developm...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Catalyst Biosciences (NASDAQ: CBIO ) stock is jumping on the sale of its protease medicines portfolio. Vertex Pharmaceuticals (NASDAQ: VRTX ) is buying it for $60 million. This is part of Catalyst Bioscienc...

Leerink has initiated Vertex Pharmaceuticals (NASDAQ:VRTX) with a market perform rating saying that the biotech needs to validate its pipeline and pursue more M&A to diversify. The firm has a $265 price target (~2% upside based on Friday's close). Analyst David Risinger said that while gr...

Penny stocks are shares of companies that trade for less than $5. While some people may have their own definitions, this is generally considered the standard. Whatever the case, the goals are the same: make money and repeat the process. One of the most exciting things about finding chea...

The clinical-stage biotech Catalyst Biosciences (NASDAQ:CBIO) announced on Monday that cystic fibrosis drugmaker, Vertex Pharmaceuticals (VRTX) signed an asset purchase and sale agreement with the company to acquire a group of product candidates for $60 million in cash. Nano-cap Catalyst Bio ...

SOUTH SAN FRANCISCO, Calif., May 23, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that it has signed a definitive asset purchase and sale agreement with Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) under which Vertex has acquired Catalyst’s...

Catalyst Biosciences press release (NASDAQ:CBIO): Q1 GAAP EPS of -$0.46 misses by $0.02. Revenue of $0.8M (-45.6% Y/Y). Cash and cash equivalents as of March 31, 2022, were $34.8 million. Shares -4.99% PM. For further details see: Catalyst Biosciences GAAP EPS of -$0.46 misses by $0.02,...

SOUTH SAN FRANCISCO, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the first quarter ended March 31, 2022. “In the first quarter, we regained the rights to CB 2782-PEG, a C3 degrader pr...

Catalyst Biosciences press release (NASDAQ:CBIO): FY GAAP EPS of -$2.87 misses by $0.01. Revenue of $7.34M (-65.0% Y/Y) beats by $2.19M. Shares +3% PM. For further details see: Catalyst Biosciences GAAP EPS of -$2.87 misses by $0.01, revenue of $7.34M beats by $2.19M

SOUTH SAN FRANCISCO, Calif., March 31, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the fourth quarter and year ended December 31, 2021 and provided a corporate update. “In late 2021 we announced a st...